Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Case Report
  • Published:

Effects of GLP1 receptor analogues in obesity with neurodevelopmental disorder: case report of a patient with holoprosencephaly

Abstract

Holoprosencephaly is an anomaly in the division of the prosencephalon into cerebral hemispheres during the second month of gestation. Patients can present with early-onset obesity favoured by the cognitive impairment. We present a case of a 24 year-old woman with holoprosencephaly and class III obesity who was treated by 2.4 mg/week SEMAGLUTIDE. Her body weight decreased from 115.3 to 94.3 kg after one-year (18% of total body weight loss). In addition, she presented a marked reduction in self- and hetero-aggressive behaviour when exposed to the sight of food. The treatment was well tolerated, with the exception of a few vomiting when eating palatable food too quickly. GLP1-RAs may be interesting for obesity treatment in the context of neurodevelopmental disorders. They appear to reduce compulsive eating and aggressive behaviour, particularly in relation to exposure to food, and lead to weight loss similar to that seen in people without neurodevelopmental disorders.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Fatnassi R, Turki E, Belhaj J, Labidi I, Ben Regaya L, Hidar S, et al. Holoprosencephaly: pathogenesis, phenotypic characteristics. About four cases. Morphologie. 2011;95:79–82.

    Article  CAS  PubMed  Google Scholar 

  2. Dubourg C, Lazaro L, Blayau M, Pasquier L, Durou MR, Odent S, et al. Genetic study of holoprosencephaly. Ann Biol Clin (Paris). 2003;61:679–87.

    CAS  PubMed  Google Scholar 

  3. Traggiai C, Stanhope R. Body mass index and hypothalamic morphology on MRI in children with congenital midline cerebral abnormalities. J Pediatr Endocrinol Metab. 2004;17:219–21.

    Article  CAS  PubMed  Google Scholar 

  4. Treasure J, Duarte TA, Schmidt U. Eating disorders. Lancet. 2020;395:899–911.

    Article  PubMed  Google Scholar 

  5. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989–1002.

    Article  CAS  PubMed  Google Scholar 

  6. Xu D, Nair A, Sigston C, Ho C, Li J, Yang D, et al. Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations. Cardiovasc Ther. 2022;2022:6820377.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Meissner WG, Remy P, Giordana C, Maltête D, Derkinderen P, Houéto J-L, et al. Trial of lixisenatide in Early Parkinson’s disease. N Engl J Med. 2024;390:1176–85.

    Article  CAS  PubMed  Google Scholar 

  8. Richards J, Bang N, Ratliff EL, Paszkowiak MA, Khorgami Z, Khalsa SS. Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: a retrospective cohort study. Obes Pillars. 2023;7:100080.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Castren ML, Jarvinen A, Laine MK, Tikkanen R. Beneficial effects of GLP-1 agonist in a male with compulsive food-related behavior associated with autism. Front Psychiatry. 2019;10:97.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Contributions

Both authors contributed to writing the clinical case.

Corresponding author

Correspondence to A. L. Borel.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Le Guiniec, M., Borel, A.L. Effects of GLP1 receptor analogues in obesity with neurodevelopmental disorder: case report of a patient with holoprosencephaly. Eur J Clin Nutr (2024). https://doi.org/10.1038/s41430-024-01450-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41430-024-01450-8

Search

Quick links